Revolution Medicines, Inc. (NASDAQ:RVMD – Get Free Report) insider Stephen Kelsey sold 92,531 shares of Revolution Medicines stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $202.36, for a total value of $18,724,573.16. Following the sale, the insider directly owned 291,876 shares in the company, valued at $59,064,027.36. This trade represents a 24.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Revolution Medicines Price Performance
NASDAQ RVMD traded down $0.25 during trading hours on Tuesday, reaching $204.86. The company’s stock had a trading volume of 1,268,481 shares, compared to its average volume of 2,918,653. Revolution Medicines, Inc. has a 1 year low of $42.18 and a 1 year high of $224.31. The company has a quick ratio of 11.38, a current ratio of 11.38 and a debt-to-equity ratio of 0.40. The company has a market capitalization of $43.91 billion, a price-to-earnings ratio of -23.23 and a beta of 1.40. The firm’s 50-day moving average price is $198.96 and its 200-day moving average price is $157.30.
Revolution Medicines (NASDAQ:RVMD – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($3.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.04) by ($1.02). During the same quarter in the previous year, the company posted ($1.31) EPS. On average, equities research analysts predict that Revolution Medicines, Inc. will post -8.87 EPS for the current fiscal year.
Institutional Inflows and Outflows
Wall Street Analyst Weigh In
RVMD has been the subject of a number of research analyst reports. Raymond James Financial restated a “strong-buy” rating and set a $248.00 price objective on shares of Revolution Medicines in a research report on Thursday, August 27th. Guggenheim increased their price target on Revolution Medicines from $240.00 to $275.00 and gave the company a “buy” rating in a research note on Friday, August 28th. Royal Bank Of Canada upped their price objective on Revolution Medicines from $203.00 to $251.00 and gave the stock an “outperform” rating in a report on Thursday, August 27th. Evercore reiterated an “outperform” rating and set a $320.00 target price on shares of Revolution Medicines in a research report on Thursday, August 27th. Finally, Wolfe Research reissued an “outperform” rating and issued a $220.00 target price on shares of Revolution Medicines in a report on Monday, August 10th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Revolution Medicines currently has an average rating of “Moderate Buy” and an average price target of $226.17.
Read Our Latest Analysis on RVMD
About Revolution Medicines
Revolution Medicines, Inc is a clinical-stage biotechnology company focused on developing targeted treatments for cancer. The company specializes in therapies designed to inhibit oncogenic RAS signaling, a pathway involved in many difficult-to-treat cancers, including tumors driven by KRAS mutations.
Its pipeline includes investigational RAS(ON) inhibitors intended to target active forms of RAS proteins. Key programs have included daraxonrasib (RMC-6236), an oral inhibitor being studied in cancers with a range of RAS mutations, as well as mutation-selective programs such as RMC-9805 for KRAS G12D and RMC-6291 for KRAS G12C.
Featured Stories
- Five stocks we like better than Revolution Medicines
- Running on Empty: 3 Energy Plays for Europe’s Deep Freeze
- 3 Healthcare Stocks for 3 Stages of Life
- Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis Bid
- MarketBeat’s Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
